Company profile

Anterogen

Adipose stem-cell therapeutics

065660 · KOSDAQ · South Korea

Public Market Listing

065660KOSDAQ

KOSDAQ primary exchange listing

Live quotes, historical charts, and market capitalization for Anterogen are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Cupistem / ALLO-ASC(Cupistem (autologous, approved in Korea))
Phase 1
Adipose-derived MSC therapyCell therapy
Inflammatory Bowel Disease
Crohn's Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.